The availability of molecular profiles of patients’ tissue at diagnosis and during treatment is critical for the selection of patients for clinical trials with molecularly targeted drugs and for studying mechanisms of clinical resistance in primary material. The UCT has extensively collected biomaterial with annotated clinical data across all tumor entities (iBDF) in addition to disease-specific projects within national/international study groups – both of which are ideally suited for molecular profiling programs.
Importantly, a proteomics facility has been set up at the UCT to study the proteome composition and posttranslational modifications (PTM, i.e. phosphorylation, acetylation, methylation, ubiquitination) in cancer models using proteomic and quantitative mass spectrometry (qMS)-based analyses. These techniques have recently been further developed for analyses of PTM in clinical samples (fresh frozen as well as formalin-fixed, paraffin-embedded, FFPE).